Advertisement

Search Results

Advertisement



Your search for Richard I. Fisher, MD matches 21 pages

Showing 1 - 21


lymphoma

Bruce D. Cheson, MD, and Richard I. Fisher, MD, on Lymphoma: Treatment Considerations

Bruce D. Cheson, MD, of Georgetown University Hospital, and Richard I. Fisher, MD, of Fox Chase Cancer Center, discuss ways to incorporate PET and CT scanning into standard of care for and research studies on lymphoma.

Mariusz A. Wasik, MD, Joins Fox Chase as Chair of Pathology

MARIUSZ A. WASIK, MD, has been appointed Chair of the Department of Pathology at Fox Chase Cancer Center and Jeanes Hospital. He will also serve as Associate Director of the Cancer Center, a position he assumed on July 2, 2018.  As Chair of Pathology and a key member of Fox Chase’s leadership...

legislation

Impact of Proposed Cuts to NIH Budget: More Than Just About Cancer

If enacted, the proposed budget reduction of $5.8 billion to the National Institutes of Health (NIH) will slow research, deprive patients afflicted with cancer of hope, and deliver a devastating blow to our science workforce and the Commonwealth of Pennsylvania. This proposed reduction directly...

Martin J. Edelman, MD, Joins Fox Chase Cancer Center as Chair of the Department of Hematology/Oncology

Martin J. Edelman, MD, an expert in the research and treatment of lung cancer, has joined Fox Chase Cancer Center, Philadelphia, as Chair of the Department of Hematology/Oncology. He will also serve as Deputy Cancer Center Director for Clinical Research, leading the effort to integrate discoveries ...

lymphoma

Interim PET-Adapted Treatment in Advanced Hodgkin Lymphoma

The ability to cure a majority of patients with advanced Hodgkin lymphoma is one of the major milestones of success in the combination chemotherapy era. It has been over 40 years since Bonadonna and colleagues in Milan developed the ABVD regimen (doxorubicin, bleomycin, vinblastine, and...

lymphoma

Richard I. Fisher, MD, on Defining and Treating Grey Zone Lymphoma

Richard I. Fisher, MD, of Fox Chase Cancer Center-Temple Health, discusses this rare disease––with features between classical Hodgkin lymphoma and primary mediastinal large B-cell lymphoma––and reviews the clinical data on treatment.

In Memoriam

The ASCO Post remembers the following specialists in oncology who passed away in 2015–2016. Please write to editor@ASCOPost.com to recognize and pay tribute to others in a future issue. Mark R. Green, MD January 3, 1945–February 23, 2015 “Few people have impacted cancer clinical research in the...

Seven New Members Elected to Interurban Clinical Club

The historic Interurban Clinical Club has announced the election of seven new members. They were elected at the group’s 213th meeting on April 1 in New York and will be welcomed at the group’s next meeting in November 2016 in Philadelphia. James E. Bradner, MD: Staff Physician at Dana-Farber...

Expert Point of View: Richard I. Fisher, MD

Richard I. Fisher, MD, the Samuel E. Durand Professor of Medicine at the University of Rochester Medical Center in Rochester, New York, cautioned that it is too early to embrace the bendamustine/rituximab regimen. Caution Advised “Bendamustine is a very active agent with moderate toxicity that...

Predictors and Treatment for Transformed Lymphoma: Current Paradigms

At the recent Pan Pacific Lymphoma Conference, held in Maui, Hawaii, Richard I. Fisher, MD, Chairman of the SWOG Lymphoma Committee and Vice-President for Strategic and Program Development at the University of Rochester Medical Center in New York, gave a presentation on the characteristics and...

Richard I. Fisher, MD, to Join Fox Chase Cancer Center and Temple University School of Medicine

On March 1, 2013, leading cancer center administrator and nationally recognized hematology/oncology expert Richard I. Fisher, MD, will assume leadership roles at Fox Chase Cancer Center, a member of the Temple University Health System, and Temple University School of Medicine, Philadelphia....

American Association for Cancer Research Inaugurates the First Class of Fellows of the AACR Academy

The American Association for Cancer Research (AACR) inaugurated the first class of Fellows of the AACR Academy at the association’s annual meeting held this month in Washington, DC. The AACR Academy has been created to recognize and honor distinguished scientists whose major scientific...

Richard I. Fisher, MD, Named President and CEO of Fox Chase Cancer Center

Richard I. Fisher, MD, has been appointed President and Chief Executive Officer of Fox Chase Cancer Center in Philadelphia. Dr. Fisher will also hold the title of Cancer Center Director of Fox Chase, serving as the Principal Investigator on the Cancer Center Support Grant from the National Cancer...

SIDEBAR: Highlights From Fox Chase Cancer Center 

1945: Hugh J. Creech, PhD, begins his 31-year career at the Institute. Dr. Creech would become widely recognized for pioneering work in developing chemotherapy agents. 1959: Peter C. Nowell, MD, University of Pennsylvania School of Medicine, and his research fellow David A. Hungerford, Fox Chase...

New President and CEO of Fox Chase Cancer Center Reflects on Challenges and Opportunities Ahead 

On October 8, 1904, a group of Philadelphia physicians and businessmen who were concerned about the escalating incidence of cancer in the city signed a charter that established the American Oncologic Hospital, one of the nation’s first hospitals solely devoted to cancer care. Seven decades later—2...

lymphoma

S9704 Trial: Autologous Transplantation as Consolidation in Aggressive Lymphoma

Autologous bone marrow or stem cell transplantation has had an important role in the treatment of aggressive lymphoma for several decades. The important results of the PARMA study1 demonstrated that patients in first relapse who remained chemosensitive had improved progression-free and overall...

health-care policy

The Evolution of U.S. Cooperative Group Trials: Publicly Funded Cancer Research at a Crossroads

Over the past 5 decades, National Cancer Institute (NCI) Clinical Trials Cooperative Groups have played an enormous role in the fight against cancer, tackling a broad social agenda, including cancer prevention, quality-of-life issues for patients with cancer, and comparison of benefits among...

kidney cancer

A Conversation With Arie Belldegrun, MD, FACS, and Allan Pantuck, MD, MS, FACS

Cancer Immunotherapy What is the role of immunotherapy in the treatment of metastatic renal cell carcinoma? The harnessing of the immune system as an effective treatment for cancer was recently selected by the journal Science as the top scientific Breakthrough of the Year for 2013.1 With this...

lymphoma

ECOG E4402/RESORT Trial: When ‘Black and White’ Results Are Actually Gray

The results of the ECOG E4402/RESORT trial recently reported by Kahl and colleagues,1 and reviewed in this issue of The ASCO Post, provide interesting new information on the use of maintenance rituximab (Rituxan) vs retreatment with rituximab at progression in patients with low–tumor burden...

Drew Ridge, MD, PhD, FACS, Elected to Medical Staff President at Fox Chase Cancer Center–Temple Health

John Andrew “Drew” Ridge, MD, PhD, FACS, Chief of Head and Neck Surgery and Louis Della Penna Family Chair in Head and Neck Oncology at Fox Chase Cancer Center–Temple Health, has been elected President of the Medical Staff at the Center. In his new role, Dr. Ridge will work with President and CEO...

Richard I. Fisher, MD, Named President and CEO of Fox Chase Cancer Center

Richard I. Fisher, MD, a leading cancer center administrator and nationally recognized hematology/oncology expert, has been appointed President and CEO of Fox Chase Cancer Center. Dr. Fisher will also hold the title of Cancer Center Director of Fox Chase, serving as the principal investigator on...

Advertisement

Advertisement



;
Advertisement